Peptide and Anticoagulant Drug Market
Global Peptide and Anticoagulant Drug Market Size, Share & Trends Analysis Report by Product (Hormonal, Antibiotic, Antifungal, ACE inhibitor, and others) and by Application (Diabetes, Cancer, Osteoporosis, Cardiology, Gynecology, Infectious Diseases, and Others) Forecast (2022-2028)
The peptide and anticoagulant drugs market is projected to register a CAGR of 3.3% during the forecast period (2022-2028). Peptides are a chain of amino acids. Anticoagulants are blood thinners that prevent coagulation of blood, prolonging the clotting time. The peptide and anticoagulant drugs are used for myocardial infarction, pulmonary embolism, stroke, and others. Increasing healthcare expenditure is one of the driving factors in boosting the growth of the peptide and anticoagulant drug market. For instance, according to the data published by the Centre for Medicare and Medicaid Services (CMS), the US health expenditure grew by $9.7 to $4.1 trillion in 2020 and accounted for 19.1% of Gross Domestic Product (GDP). Similarly, Medicare spending grew by 3.5% to $829.1 billion in 2020 which is 20 % of total national health expenditure. Whereas, Medicaid spending grew by 9.2% to $671.2 billion in 2020, which is 16 % of total national health expenditure. Moreover, according to CMS, national health spending is anticipated to grow at an average annual rate of 5.4 % and to reach $6.2 trillion by 2028.
Impact of COVID-19 on Global Peptide and Anticoagulant Drug Market.
COVID-19 has caused a significant impact on the global peptide and anticoagulant drug market. The sponsors and clinical research organizations that support drug development shifted to the remote working environment. Also, non-COVID procedures were interrupted due to the COVID-19 pandemic, which directly had an impact on the market. However, according to the article published by National Center for Biotechnology Information (NCBI), COVID-19 had a positive impact on the peptide drug market as peptide drugs were considered as a treatment option for dealing with COVID-19.
Segmental outlook
The global peptide and anticoagulant drug market are segmented based on product and application. Based on the product, the market is further sub-segmented into Hormonal, antibiotic, antifungal, ACE inhibitor, others. Based on application, the market is sub-segmented into diabetes, cancer, osteoporosis, cardiology, gynecology, infectious diseases, others. Among these, the antibiotics segment is expected to hold a considerable share in the market during the forecast period owing to an incline in bacterial infections.?
Global Peptide and Anticoagulant Drug Market Share by Application, 2021 (%)
The Cardiology Segment is Anticipated to Hold a Prominent Share in the Global Peptide and Anticoagulant Drug Market
An increase in cardiovascular diseases is accelerating the growth of the cardiology segment in the market. For instance, according to the Heart Disease and Stroke Statistics Update Fact sheet published in 2021, cardiovascular diseases are leading the cause of death and accounted for around 18.6 million mortalities in 2019. In addition, according to World Health Organization (WHO), ischemic heart disease is responsible for about 16% of the world's total mortalities. cardiovascular diseases claim more lives than all forms of cancer and chronic lower respiratory disease (CLRD). Moreover, according to the article Anticoagulation Therapy for Non-valvular Atrial Fibrillation published in July 2020, anticoagulant drug plays a significant role in patients suffering from arterial fibrillation by preventing blood clots, heart stroke, heart failure, and other heart-related complications. Thus, the adoption of these drugs in cardiovascular diseases is anticipated to drive the growth of the global peptide and anticoagulant drug market.
Regional Outlook
The global peptide and anticoagulant drug market are further segmented based on geography including North America, Europe, Asia Pacific, and the rest of the world. The market can be analyzed for a particular region or country level as per the requirement. Asia-Pacific region is anticipated to hold a considerable share in the market during the forecast period owing to an increase in health awareness and cardiovascular diseases.
Global Peptide and Anticoagulant drug market Growth, by Region 2022-2028
North America Region is Anticipated to Hold a Prominent Share in the Global Peptide and Anticoagulant Drug Market
The North American region is anticipated to hold a prominent share in the market owing to the increasing necessity for diagnostics in cancer and other diseases with a high demand for peptide and anticoagulant drugs. For instance, according to the estimates provided by Cancer Facts and Figures 2020, an estimated 1.8 million new cases cancer cases were diagnosed in 2020 and 60,652 million cancer deaths were reported in the US. Further, according to the data published by Surveillance, Epidemiology, and End Results (SEER) in 2021, the statistics reported roughly 1.9 million people are diagnosed with cancer in the US. Prostate cancer was found common cancer among men and women with 248,530 cases. Thus, the rising demand for peptide and anticoagulant drugs is anticipated to witness significant growth in North America over the forecast period.
Market Players Outlook.
The major market players serving the global peptide and anticoagulant drug market are Abbott Laboratories, Johnson & Johnson Services Inc, Bayer AG, Sun Pharmaceuticals Industries Ltd and Pfizer Inc., among others. The players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2020, Takeda Pharmaceutical Co, and PeptiDream Inc entered into collaborative research and exclusive license agreement to create peptide-drug conjugates (PDCs) for neuromuscular diseases. The aim of this acquisition is to develop a new PDC drug to treat neuromuscular diseases.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global peptide and anticoagulant drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Peptide and Anticoagulant Drug Market
- Recovery Scenario of Global Peptide and Anticoagulant Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Abbott Laboratories
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bayer AG
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Pfizer, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Sun Pharmaceutical Industries Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Johnson & Johnson Services, Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Peptide and anticoagulant drug Market by Product
4.1.1. Antibiotics
4.1.2. Antifungal
4.1.3. ACE Inhibitor
4.1.4. Hormonal
4.2. Global Peptide and anticoagulant drug Market by application
4.2.1. Cardiology
4.2.2. Gynecology
4.2.3. Diabetes
4.2.4. Cancer
4.2.5. Osteoporosis
4.2.6. Infectious Diseases
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Amgen,Inc
6.2. Aspen Pharmacare Holdings, Ltd.
6.3. AmbioPharm,Inc.
6.4. Boehringer Ingelheim International GmbH
6.5. Bristol-Myers Squibb Co.
6.6. Biofera Laboratories Pvt Ltd.
6.7. BACHEM AG
6.8. Daiichi Sankyo Co.
6.9. EVER Pharma
6.10. Dr.Reddys Laboratories , Ltd.
6.11. LEO Pharma A/S
6.12. SANOFI
6.13. Novartis AG
6.14. Novo Nordisk A/S
6.15. Takeda Pharmacuetical Co ,Ltd.
6.16. Teva Pharmaceutical Industries
6.17. Wockhardt Ltd.
1. GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
2. GLOBAL ANTIBIOTICS PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL ACE INHIBITOR PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL HORMONAL PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
5. GLOBAL ANTIFUNGAL PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL CARDIOLOGY IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL GYNECOLOGY IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL DIABETES IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CANCER IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL OSTEOPOROSIS IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL INFECTIOUS IN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. NORTH AMERICAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
16. NORTH AMERICAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. EUROPEAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. EUROPEAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
19. EUROPEAN PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT 2021-2028 ($ MILLION)
22. ASIA-PACIFIC PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
23. REST OF THE WORLD PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. REST OF THE WORLD PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
25. REST OF THE WORLD PEPTIDE AND ANTICOAGULANT DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET, 2021-2028 (%)
4. GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY PRODUCT, 2021VS 2028 (%)
5. GLOBAL ANTIBIOTICS IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL ACE INHIBITOR IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL HORMONAL PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
8. GLOBAL ANTIFUNGAL IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
9. GLOBAL PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY APPLICATION, 2021VS 2028 (%)
10. GLOBAL CARDIOLOGY PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
11. GLOBAL GYNECOLOGY IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
12. GLOBAL DIABETES FOR PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
13. GLOBAL CANCER IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
14. GLOBAL OSTEOPOROSIS IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
15. GLOBAL INFECTIOUS DISEASES IN PEPTIDE AND ANTICOAGULANT DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
16. US PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. UK PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD PEPTIDE AND ANTICOAGULANT DRUG MARKET SIZE, 2021-2028 ($ MILLION)
